MediGene AG - Company Profile
Powered by 
All the data and insights you need on MediGene AG in one report.
$295
- Save hours of research time and resources with
our up-to-date MediGene AG Strategy Report
- Understand MediGene AG position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
MediGene AG (MediGene) is a biotechnology company which develops innovative immunotherapies to treat cancer with candidates in clinical and pre-clinical development. It focuses on the development of personalized T-cell-based immunotherapies. Its core business develops three immunotherapy platforms including DC vaccines to kill tumor cells; T-cell receptor (TCR) detects; and kills tumor cells and T-cell-specific monoclonal antibodies (TAB’s), for isolation of antibodies for monitoring and tracking of TCR-Ts. The company has operational presence in the US and Europe. Medigene is headquartered in Planegg, Germany.
Headquarters
Germany
Address
Lochhamer Strasse 11, Planegg, Bayern, 82152
Website
www.medigene.de
Telephone
49 89 2000330
No of Employees
86
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MDG1 (ETR)
Revenue (2022)
$6.5M
-80.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-94.2%
(2022 vs 2021)
Market Cap*
$50.4M
Net Profit Margin (2022)
XYZ
-905.6%
(2022 vs 2021)
* As of and is in US$
MediGene AG premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| MDG1011- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), |
| MDG10XX-Solid Tumors |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In April, the company and the National Cancer Institute partnered to evaluate the potential of Medigene’s proprietary T cell receptors to be used in new cell constructs for the treatment of solid tumors. |
| 2022 | Contracts/Agreements | In February, the company and Biontech announced collaboration to advance T cell receptor immunotherapies against cancer. |
| 2020 | Patent Grant | In April, the company received two patent grants for its novel crossTAg-1 technology. |
Competitor Comparison
| Key Parameters | MediGene AG | 4SC AG | AIM ImmunoTech Inc | Ambrilia Biopharma Inc | Genentech USA Inc |
|---|---|---|---|---|---|
| Headquarters | Germany | Germany | United States of America | Canada | United States of America |
| City | Planegg | Planegg | Ocala | Montreal | South San Francisco |
| State/Province | Bayern | Bayern | Florida | Quebec | California |
| No. of Employees | 86 | 15 | 26 | - | 14,000 |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dr. Selwyn Ho | Chief Executive Officer | Senior Management | 2022 | - |
| Dolores J. Schendel Ph.D. | Chief Scientific Officer | Senior Management | 2022 | - |
| Dr. Gerd Zettlmeissl | Chairman | Non Executive Board | - | 68 |
| Pamela Keck | Head - Investor Relations and Corporate Communications; Vice President - Investor Relations and Corporate Communications | Senior Management | 2023 | - |
| Kirsty Crame, MD | Vice President; Head - Clinical Research and Development | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer